TogoTuberculosis profile
Population  2014 7.1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.63 (0.44–0.85) 8.8 (6.1–12)
Mortality (HIV+TB only) 0.3 (0.23–0.38) 4.2 (3.3–5.3)
Prevalence  (includes HIV+TB) 5.8 (3.1–9.3) 81 (43–131)
Incidence  (includes HIV+TB) 4.1 (3.4–5) 58 (47–70)
Incidence (HIV+TB only) 0.83 (0.67–1) 12 (9.4–14)
         
Case detection, all forms (%) 61 (51–75)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 26 (15–40)
MDR-TB cases among notified pulmonary
TB cases
35 (6–64) 42 (24–65)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 899   110
Pulmonary, clinically diagnosed 177   0
Extrapulmonary 339   0
       
Total new and relapse 2 525    
Previously treated, excluding relapses 52    
Total cases notified 2 577    
Among 2 525 new and relapse cases:
80 (3%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 (<1%) 18 (11%) 19
Laboratory-confirmed RR-/MDR-TB cases     9
Patients started on MDR-TB treatment ***     1
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 511 (97)
HIV-positive TB patients 523 (21)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 465 (89)
HIV-positive TB patients on antiretroviral therapy (ART) 396 (76)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 2 644
Previously treated cases, excluding relapse, registered in 2013 (82) 50
HIV-positive TB cases, all types, registered in 2013   180
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 3
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-05 Data: www.who.int/tb/data